BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.76% | -2.76% | -21.79% | -22.94% | -20.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.32% | -18.38% | -30.76% | -13.86% | 13.68% |
| Operating Income | -1.32% | 18.38% | 30.76% | 13.86% | -13.68% |
| Income Before Tax | -73.48% | -438.49% | -221.90% | 7.61% | -26.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.48% | -438.49% | -221.90% | 7.61% | -26.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 139.28% | 74.30% | 95.36% | 60.49% | 191.57% |
| Net Income | -72.99% | -449.14% | -224.13% | 8.05% | -25.77% |
| EBIT | -1.32% | 18.38% | 30.76% | 13.86% | -13.68% |
| EBITDA | -1.32% | 18.49% | 31.16% | 14.23% | -13.34% |
| EPS Basic | 59.87% | -86.45% | -46.50% | 58.21% | -3.22% |
| Normalized Basic EPS | 59.85% | -89.00% | -47.12% | 58.47% | -2.93% |
| EPS Diluted | 59.86% | 53.25% | 55.97% | 80.10% | 49.16% |
| Normalized Diluted EPS | 59.85% | -79.20% | -41.17% | 59.27% | -1.08% |
| Average Basic Shares Outstanding | 567.83% | 287.12% | 120.91% | 59.29% | 21.47% |
| Average Diluted Shares Outstanding | 567.83% | 283.02% | 118.49% | 57.53% | 20.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |